top of page
_edited.jpg

METABOLIC / FDA APPROVED

Subcutaneous injection (weekly)

Overview

A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604 retains the lipolytic activity of hGH without its growth-promoting or diabetogenic effects.

Mechanism of Action

It stimulates lipolysis and inhibits lipogenesis through a mechanism distinct from the GH receptor, acting on beta-3 adrenergic receptors in adipose tissue.

​Research Summary & Key Findings

Preclinical studies showed significant fat reduction without effects on IGF-1, glucose, or insulin levels. Phase 2b clinical trial showed modest but statistically significant weight reduction. TGA (Australia) approved as a food supplement. Limited Phase 3 clinical evidence.

Clinical Status

INVESTIGATIONAL

AOD-9604 is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

Administration Routes

Subcutaneous injection (weekly)

Oral (daily - Rybelsus)

References

PRIMARY LITERATURE

PRIMARY LITERATUREPeer-reviewed literature indexed by the National Library of Medicine.

Registered interventional and observational studies, including status and phase.

Chemical structure, molecular properties, and bioactivity data.

Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.

Administration Routes

METABOLIC

An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds…

METABOLIC

Tirzepatide (Mounjaro/Zepbound)

A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways…

METABOLIC

AOD-9604

A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604…

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.

bottom of page